MCID: PRP036
MIFTS: 51

Peripheral T-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Peripheral T-Cell Lymphoma

MalaCards integrated aliases for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 11 19 75 14 36 71
Lymphoma T-Cell Peripheral 53

Classifications:



External Ids:

Disease Ontology 11 DOID:0050749
ICD10 31 C84.4
UMLS 71 C0079774

Summaries for Peripheral T-Cell Lymphoma

GARD: 19 A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.

MalaCards based summary: Peripheral T-Cell Lymphoma, also known as lymphoma t-cell peripheral, is related to angioimmunoblastic t-cell lymphoma and burkitt lymphoma, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TNFRSF8 (TNF Receptor Superfamily Member 8), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Ifosfamide and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, thymus and t cells, and related phenotypes are immune system and neoplasm

Disease Ontology: 11 A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus.

Wikipedia: 75 Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the... more...

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 560)
# Related Disease Score Top Affiliating Genes
1 angioimmunoblastic t-cell lymphoma 32.5 TNFRSF8 TIA1 MME ITK CXCL13 CD8A
2 burkitt lymphoma 32.2 TP53 TNFRSF8 TCL1A STAT3 NME1 MS4A1
3 lymphoma 32.0 TP53 TNFRSF8 TIA1 TCL1A STAT3 MS4A1
4 anaplastic large cell lymphoma 32.0 TNFRSF8 STAT3 GZMB CXCR3 CCR4 BCL2
5 nasal type extranodal nk/t-cell lymphoma 31.9 TNFRSF8 TIA1 GZMB
6 lymphoma, hodgkin, classic 31.7 TP53 TNFRSF8 TIA1 STAT3 MS4A1 GZMB
7 diffuse large b-cell lymphoma 31.7 TNFRSF8 MME CD5 BCL6 BCL2
8 adult t-cell leukemia/lymphoma 31.7 TP53 TNFRSF8 CD8A CD5 CCR4 BCL2
9 panniculitis 31.6 TIA1 GZMB CD8A
10 t-cell acute lymphoblastic leukemia 31.6 TNFRSF8 TCL1A STAT3 CD8A CD5 CCR4
11 primary cutaneous t-cell non-hodgkin lymphoma 31.6 TNFRSF8 TIA1 STAT3 GZMB CXCR3 CD5
12 b-cell lymphoma 31.4 TP53 TNFRSF8 TIA1 TCL1A STAT3 MS4A1
13 reticulosarcoma 31.4 TNFRSF8 TIA1 GZMB BCL6 BCL2 ALK
14 mycosis fungoides 31.4 TP53 TNFRSF8 TIA1 STAT3 GZMB CXCR3
15 pancytopenia 31.4 TP53 MME ITK CD8A CD5
16 composite lymphoma 31.3 TNFRSF8 MME CD5 BCL6 BCL2
17 lymphoproliferative syndrome 31.3 TNFRSF8 TIA1 TCL1A STAT3 ITK CD5
18 b-cell non-hodgkin lymphoma 31.3 MS4A1 BCL6
19 hemophagocytic lymphohistiocytosis 31.2 ITK GZMB CD8A
20 lymphoblastic lymphoma 31.2 TNFRSF8 MS4A1 CD8A BCL6 BCL2
21 hepatosplenic t-cell lymphoma 31.2 TNFRSF8 TIA1 GZMB CD8A CD5 ALK
22 marginal zone b-cell lymphoma 31.2 TNFRSF8 MME CD5 BCL6 BCL2
23 t-cell adult acute lymphocytic leukemia 31.2 TP53 TNFRSF8 TIA1 CD8A CD5 CCR4
24 mature t-cell and nk-cell lymphoma 31.1 TP53 TNFRSF8 TIA1 STAT3 MME GZMB
25 dermatitis 31.1 STAT3 GZMB CXCR3 CCR4
26 lymphoma, non-hodgkin, familial 31.1 TP53 TNFRSF8 TCL1A STAT3 MS4A1 MME
27 follicular lymphoma 31.0 TP53 TCL1A STAT3 MS4A1 MME CD5
28 lethal midline granuloma 31.0 TNFRSF8 TIA1 GZMB CD5
29 leukemia 31.0 TP53 TCL1A STAT3 MME ETV6 BCL2
30 celiac disease 1 31.0 TNFRSF8 TIA1 STAT3 GZMB CXCR3 CD8A
31 prolymphocytic leukemia 31.0 TP53 TCL1A MS4A1 CD5
32 peripheral nervous system disease 31.0 TP53 TNFRSF8 STAT3 MME CD8A BCL2
33 leukemia, chronic lymphocytic 2 30.9 MS4A1 CD5 BCL2
34 immune deficiency disease 30.9 TNFRSF8 MS4A1 CXCR3 CD8A CD5 CCR4
35 skin benign neoplasm 30.9 TP53 STAT3 FGFR3
36 lymphoproliferative syndrome, x-linked, 1 30.9 TNFRSF8 TIA1 ITK GZMB CXCR3 CCR4
37 central nervous system lymphoma 30.9 TNFRSF8 MME CXCL13 CD5 BCL6 BCL2
38 breast lymphoma 30.8 TNFRSF8 MME CD5 BCL6 BCL2 ALK
39 sezary's disease 30.8 TP53 TNFRSF8 TIA1 STAT3 CD8A CD5
40 lymphatic system disease 30.8 TP53 TNFRSF8 MME CD8A CD5 BCL6
41 testicular lymphoma 30.8 TNFRSF8 MME BCL6 BCL2
42 seminoma 30.8 TP53 TNFRSF8 TCL1A NME1
43 lung lymphoma 30.8 TNFRSF8 MME CD5 BCL6
44 chronic lymphocytic leukemia/small lymphocytic lymphoma 30.7 TP53 TNFRSF8 MME CD5 BCL6 BCL2
45 leukemia, acute lymphoblastic 30.7 TP53 TCL1A MME ETV6 CXCR3 CD8A
46 t-cell prolymphocytic leukemia 30.7 TP53 TNFRSF8 TCL1A CD8A CD5 ALK
47 lymphoma, mucosa-associated lymphoid type 30.7 TP53 TNFRSF8 MME CXCR3 CXCL13 CD5
48 dermatitis, atopic 30.7 TNFRSF8 STAT3 CXCR3 CD8A CCR4
49 leukemia, chronic lymphocytic 30.7 TP53 TNFRSF8 TCL1A STAT3 MS4A1 MME
50 lymphomatoid granulomatosis 30.7 TIA1 GZMB

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:



Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


pruritus

GenomeRNAi Phenotypes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 ALK BCL2 BCL6 CCR4 CD5 CD8A
2 no effect GR00402-S-2 10.15 ALK BCL2 BCL6 CCR4 CD5 CXCL13

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.09 BCL2 BCL6 CCR4 CD5 CD8A CXCL13
2 neoplasm MP:0002006 10.06 ALK BCL2 CXCR3 ETV6 FGFR3 GZMB
3 cellular MP:0005384 10.03 BCL2 BCL6 CD8A CXCL13 CXCR3 ETV6
4 normal MP:0002873 10.02 ALK BCL6 CD5 CD8A CXCR3 ETV6
5 endocrine/exocrine gland MP:0005379 10.02 ALK BCL2 BCL6 CD8A ETV6 ITK
6 hematopoietic system MP:0005397 9.86 BCL2 BCL6 CCR4 CD5 CD8A CXCL13
7 integument MP:0010771 9.36 ALK BCL2 BCL6 CD5 CD8A ETV6

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 4 3778-73-2 3690
2
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
3
Cisplatin Approved Phase 4 15663-27-1 2767 5702198 441203
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
6
Pegaspargase Approved, Investigational Phase 4 130167-69-0
7
Asparaginase Escherichia coli Approved, Investigational Phase 4 9015-68-3
8
Coenzyme M Approved, Investigational Phase 4 3375-50-6 598 23662354
9
Denileukin diftitox Approved, Investigational Phase 4 173146-27-5
10
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
11
Infliximab Approved Phase 4 170277-31-3
12
Methoxsalen Approved Phase 4 298-81-7 4114
13
Golimumab Approved Phase 4 476181-74-5
14
Brentuximab vedotin Approved, Investigational Phase 4 914088-09-8
15
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
16
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
17
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 4 133585-56-5, 60-18-4, 556-02-5 1153 6057
18
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
20
Palifosfamide Investigational Phase 4 31645-39-3 100427
21
Pirarubicin Investigational Phase 4 72496-41-4 4844
22 Protective Agents Phase 4
23 Antiemetics Phase 4
24 BB 1101 Phase 4
25 HIV Protease Inhibitors Phase 4
26
protease inhibitors Phase 4
27 N-Methylaspartate Phase 4
28 Gastrointestinal Agents Phase 4
29 Pharmaceutical Solutions Phase 4
30 Photosensitizing Agents Phase 4
31 Tumor Necrosis Factor Inhibitors Phase 4
32 Antineoplastic Agents, Immunological Phase 4
33 Immunologic Factors Phase 4
34 Dermatologic Agents Phase 4
35 Folic Acid Antagonists Phase 4
36 Folate Phase 4
37 Vitamin B9 Phase 4
38 Vitamin B Complex Phase 4
39 Antiviral Agents Phase 4
40 Anti-Infective Agents Phase 4
41 Antimetabolites Phase 4
42 Immunosuppressive Agents Phase 4
43 interferons Phase 4
44 Interferon alpha-2 Phase 4
45 Interferon-alpha Phase 4
46
Clorazepate Dipotassium Phase 4
47
Vinblastine Approved Phase 3 865-21-4 241903 13342
48
Bleomycin Approved, Investigational Phase 3 9041-93-4, 11056-06-7 5360373
49
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
50
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426

Interventional clinical trials:

(show top 50) (show all 531)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Unknown status NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
2 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma Unknown status NCT04040491 Phase 4 PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
3 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unknown status NCT03631862 Phase 4 Apatinib;CHOP Regimen
4 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Unknown status NCT03150602 Phase 4 Pralatrexate
5 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma Unknown status NCT04038411 Phase 4 PD-1 Antibody, chidamide, lenalidomide and etoposide
6 A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Unknown status NCT04490590 Phase 4 Chidamide+ Etoposide
7 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
8 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
9 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
10 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
11 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
12 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
13 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
14 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab
15 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
16 A Phase 4, Single Arm, Open Label, Multicenter Study of Brentuximab Vedotin Treatment of Chinese Patients With CD30-Positive Cutaneous T-Cell Lymphoma Recruiting NCT05442554 Phase 4 Brentuximab vedotin
17 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Terminated NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
18 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
19 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
20 Multi-center Randomized Study to Compare Efficacy and Safety of Decitabine Plus CHOP (D-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Unknown status NCT03553537 Phase 3 Decitabine;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
21 Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies Unknown status NCT03623087 Phase 3 Cisplatin;Gemcitabine;Etoposide (VP-16);Dexamethasone;L-asparaginase
22 A Prospective , Multicenter, RandomizedPhase III Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients Unknown status NCT01788137 Phase 3 chemotherapy (CHOP);chemotherapy(c-ATT)
23 A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT01482962 Phase 3 Alisertib;Pralatrexate;Gemcitabine;Romidepsin
24 A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT03349333 Phase 3 pralatrexate
25 Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP Completed NCT00970385 Phase 3 CHOP21;VIP/ABVD
26 A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas Completed NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
27 A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma Completed NCT01871727 Phase 3 E7777 9 mcg/kg
28 An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma Completed NCT00877656 Phase 2, Phase 3
29 A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma Completed NCT02448381 Phase 3 SGX301 (synthetic hypericin);Placebo
30 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
31 Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma Completed NCT01728805 Phase 3 Vorinostat
32 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
33 Efficacy and Safety of Cladribine Combined With BEAC ( Semustine, Etoposide, Cytarabine, Cyclophosphamide) Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study Recruiting NCT04880746 Phase 3 BEAC;Cladribine combined with BEAC
34 Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03952572 Phase 3 Cyclophosphamide;pegylated liposomal doxorubicin;Vincristine;Prednisone;Doxorubicin
35 PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients:a Randomized, Open-label, Phase 3 Study Recruiting NCT02085655 Phase 3 pegaspargase;Gemcitabine;Oxaliplatin;Methotrexate;Dexamethasone;Thalidomide
36 A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) Recruiting NCT04365036 Phase 3 Toripalimab;Pegaspargase;Gemcitabine;Oxaliplatin
37 Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma Active, not recruiting NCT01796002 Phase 3 Romidepsin + CHOP;CHOP
38 Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Active, not recruiting NCT03703375 Phase 3 Azacitidine;Romidepsin;Gemcitabine
39 The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Active, not recruiting NCT02631239 Phase 3 Methotrexate;Etoposide;Dexamethasone;Pegaspargase
40 Randomized Phase 3 Study Evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patient With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Active, not recruiting NCT03593018 Phase 3 Oral azacitidine;Romidepsin;Bendamustine;Gemcitabine
41 A Randomized, Open-label, Active Controlled, Multi-center Phase 3 Clinical Study to Compare the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection With Chidamide in Patients With Relapsed/Refractory PTCL. Not yet recruiting NCT04668690 Phase 3 Mitoxantrone Hydrochloride Liposome Injection;Chidamide
42 A Prospective, Multicenter, Phase III, Non-randomized Study of Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma Not yet recruiting NCT05075460 Phase 3 Tucidinostat, Azacitidine combined with CHOP
43 A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients Previously Undiagnosed Peripheral T-cell Lymphoma Who Achieved an Objective Response After Initial Treatment With CHOP-based Chemotherapy Terminated NCT01420679 Phase 3 Pralatrexate Injection
44 Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma:a Prospective Randomized Phase III Study Terminated NCT02359162 Phase 3 Gemcitabine;Oxaliplatin;Pegaspargase;Etoposide;Vincristine;Doxorubicin;Cyclophosphamide;Prednisone
45 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT04021082 Phase 2, Phase 3 Cerdulatinib
46 A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma Withdrawn NCT01355783 Phase 3 E7777
47 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT03355768 Phase 3 Romidepsin;Pralatrexate
48 A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Unknown status NCT03278782 Phase 1, Phase 2 Romidepsin
49 A Multi-center, Prospective, Single-arm, Open Label Phase II Study of Chidamide Combined With Chemotherapy in the Treatment of Peripheral T Cell Lymphoma Unknown status NCT02753543 Phase 2 Chidamide
50 A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Unknown status NCT03321890 Phase 2 Chidamide;prednisone;Cyclophosphamide;etoposide;Methotrexate

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

Organs/tissues related to Peripheral T-Cell Lymphoma:

MalaCards : Bone Marrow, Thymus, T Cells, Bone, Skin, Liver, Nk Cells

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 2819)
# Title Authors PMID Year
1
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. 53 62
20217288 2010
2
Primary cutaneous follicular variant of peripheral T-cell lymphoma NOS. A report of two cases. 53 62
20459562 2010
3
Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. 53 62
19710685 2010
4
Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. 53 62
19377442 2009
5
[Small cell variant of peripheral T-cell lymphoma, not otherwise specified: a clinicopathologic and immunophenotypic analysis]. 53 62
19575875 2009
6
[Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified]. 53 62
19575892 2009
7
Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. 53 62
19365529 2009
8
Chemokine receptor repertoire reflects mature T-cell lymphoproliferative disorder clinical presentation. 53 62
18842429 2009
9
[Peripheral T-cell lymphoma, NOS arising in Warthin tumor: report of a case]. 53 62
19031731 2008
10
Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. 53 62
18425045 2008
11
Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas. 53 62
17582237 2007
12
Rare expression of BSAP (PAX-5) in mature T-cell lymphomas. 53 62
17431414 2007
13
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 53 62
17430665 2007
14
[Expression and clinical significance of Mcl-1 in T-cell non-Hodgkin's lymphoma]. 53 62
17430669 2007
15
[Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma]. 53 62
17166378 2006
16
Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. 53 62
16680156 2006
17
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. 53 62
16341044 2006
18
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. 53 62
16091734 2005
19
Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. 53 62
16160469 2005
20
Peripheral T-cell lymphoma not otherwise specified vs. Hodgkin's lymphoma on fine needle aspiration cytology. 53 62
16124164 2005
21
Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified. 53 62
15925824 2005
22
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML. 53 62
15514005 2005
23
Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-Cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). 53 62
15965283 2005
24
Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. 53 62
15531460 2004
25
Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. 53 62
15105810 2004
26
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 53 62
15133473 2004
27
CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. 53 62
15328188 2004
28
Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. 53 62
14616965 2003
29
Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. 53 62
12707037 2003
30
CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. 53 62
11979374 2002
31
T-cell receptor Vbeta repertoire in nodal non-anaplastic peripheral T-cell lymphomas. 53 62
12166895 2002
32
Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. 53 62
11731410 2001
33
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma. 53 62
11222361 2001
34
Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. 53 62
11235901 2001
35
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. 53 62
10786666 2000
36
Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. 53 62
10414505 1999
37
ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. 53 62
9736036 1998
38
Amplification of the TCL1 flanking region at 14q32.1 with no TCL1 gene transcription in a patient with peripheral T cell lymphoma. 53 62
9639427 1998
39
Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis. 53 62
8655683 1996
40
High-grade pleomorphic T cell lymphoma with restricted involvement of skin and bone marrow. 53 62
8513200 1993
41
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. 53 62
1373974 1992
42
[Midline malignant reticulosis: a histopathological, ultrastructural and immunohistochemical study of 11 cases]. 53 62
1813158 1991
43
Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. 53 62
1652981 1991
44
Unusual peripheral T-cell lymphoma, displaying NOS and flower cells in the blood, and CNS involvement. 62
36450368 2022
45
Impact of autologous stem cell transplantation on survival outcomes in patients with peripheral T cell lymphoma. 62
35934613 2022
46
Indolent T-cell lymphoproliferative disorder of gastrointestinal tract with unusual clinical courses: report of 6 cases and literature review. 62
36472661 2022
47
Prognostic role of controlling nutritional status score in hematological malignancies. 62
35622088 2022
48
Circulating Tumor DNA in Lymphoma. 62
36214943 2022
49
Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. 62
35864006 2022
50
Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino América (GELL)]. 62
36326296 2022

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

6 (show all 12)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

Pathways related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 ALK BCL2 CCR4 CXCL13 CXCR3 FGFR3
2 13.48 TP53 TIA1 STAT3 GZMB FGFR3 CXCR3
3
Show member pathways
13.36 ALK BCL2 CCR4 CXCL13 CXCR3 FGFR3
4
Show member pathways
12.7 STAT3 ITK CXCR3 CXCL13 CCR4
5
Show member pathways
12.5 TP53 STAT3 FGFR3 BCL2 ALK
6
Show member pathways
12.47 TP53 TNFRSF8 STAT3 ITK FGFR3 CXCR3
7
Show member pathways
12 TP53 STAT3 GZMB BCL2
8 11.95 TNFRSF8 STAT3 ITK GZMB CD8A BCL6
9 11.76 TP53 BCL6 BCL2
10 11.69 MS4A1 MME CD8A CD5
11 11.64 GZMB CXCR3 CD8A
12 11.59 TP53 FGFR3 BCL2
13 11.59 BCL2 BCL6 STAT3 TP53
14 11.57 MS4A1 MME CD8A
15 11.37 STAT3 GZMB FGFR3
16 10.63 GZMB ETV6 BCL2
17 10.55 TP53 STAT3
18 10.27 TP53 BCL2

GO Terms for Peripheral T-Cell Lymphoma

Cellular components related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 MS4A1 MME FGFR3 CXCR3 CD8A CD5
2 plasma membrane GO:0005887 9.7 MS4A1 MME FGFR3 CXCR3 CD8A CD5

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell proliferation GO:0042100 9.63 MS4A1 BCL6 BCL2
2 T cell lineage commitment GO:0002360 9.13 TP53 BCL2
3 B cell lineage commitment GO:0002326 8.92 TP53 BCL2

Sources for Peripheral T-Cell Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....